How Oily Injection Vehicles Dictate Terminal Sterilization and Filtration Boundaries for Estradiol Benzoate

Estradiol benzoate veterinary grade is practically insoluble in water, with solubility in aqueous media typically below 0.01 mg/mL at 25 °C, while solubility in sesame oil, ethyl oleate, or a benzyl benzoate/ethyl oleate co-vehicle reaches processing-relevant concentrations of 5–20 mg/mL. An injectable solution therefore is not a simple dilution exercise: the API is first dissolved in a heated oil phase at 35–45 °C under nitrogen, with a co-solvent such as 10–20% v/v benzyl benzoate added to reduce viscosity and depress the melting point of the bulk vehicle. The solution is then clarified through a 0.45 µm polypropylene depth filter, followed by sterile filtration through a 0.22 µm hydrophobic PVDF membrane. Because oil-based vehicles have dynamic viscosities commonly in the range of 40–70 mPa·s at filtration temperatures, the maximum differential pressure across the sterilizing-grade membrane must be limited to 0.6–0.8 bar to avoid filter pleat collapse and particle shedding. Terminal sterilization of the finished product is not a universal default: moist-heat autoclaving at 121 °C for 15 min can be used only if the residual water content is held below 0.1%, because free water accelerates hydrolysis of the 3-benzoate ester to 17β-estradiol. Dry-heat sterilization at 160 °C for 2 h is an alternative for fully anhydrous oil systems, but published industrial data for this specific estradiol benzoate configuration are limited, and the darker color generated by oil oxidation at that temperature may exceed product specifications. For this reason, many production lines operate aseptic filtration followed by filling in an ISO 14644-1 class 5 environment under EU GMP Annex 1 conditions. Container-closure selection is critical: type I glass vials are used with butyl rubber stoppers coated with PTFE or ETFE laminate, and silicone oil treatment on stoppers is minimized because the ester partitions into hydrophobic surfaces. A multi-dose vial therefore requires an antimicrobial preservative that does not cause phase separation or particulate growth; benzyl alcohol at 1.0–1.5% v/v is used in some veterinary formulations when the route is intramuscular, but the formulation must be checked for precipitation at 2–8 °C storage. For food-producing species, the surrounding regulatory boundary is decisive: Directive 2003/74/EC and Regulation (EU) 2019/6 prohibit the use of estradiol 17β and its esters in animals intended for human consumption within the European Union, so injectable products for cattle or sheep are manufactured only for territories where a veterinary marketing authorization exists and residue surveillance supports the use.

Tablet Compression Physics for a Low-Dose Estradiol Benzoate Matrix

Direct compression is not a technically valid option for 0.5 mg or 1.0 mg estradiol benzoate tablet strengths because the API is a light, electrostatic crystalline powder with poor flow, and the required drug load is below 1.0% w/w of a typical 100 mg core. The practical route is hydroalcoholic wet granulation, using micronized API with a particle size distribution controlled at D90 not more than 15 µm to reduce content uniformity failure. A representative binder solution is povidone K30 at 4–6% w/w in a 60:40 ethanol–water mixture; the organic fraction limits contact time between water and the ester bond during granulation. Granules are dried to a loss on drying value of ≤2.0% and milled through a 0.8 mm screen to give a granule D50 of 100–160 µm. On a rotary tablet press with 8 mm biconvex tooling, precompression force is set in the range 4–6 kN and main compression force at 10–15 kN, producing tablets with hardness 50–80 N and friability below 0.5% when tested according to Ph. Eur. 2.9.7. Content uniformity must be verified under Ph. Eur. 2.9.40 or USP <905>; for a low-dose veterinary tablet, an acceptance value of ≤15.0 is the recognized threshold, but the process should be designed for an AV below 10.0 to accommodate batch-to-batch variability in the API source. Dissolution testing for this compound is not harmonized across all veterinary pharmacopoeias, and published monographs for estradiol benzoate veterinary tablets remain limited. If a dissolution specification is applied, a common internal method is USP <711> apparatus 2 at 50 rpm with 900 mL of 0.25% sodium lauryl sulfate in phosphate buffer pH 6.8, with a Q value of 75% released at 45 min. The stabilizing package must be selected before stability data are generated: aluminum/PVC/PVDC blisters with desiccant pouches are preferred, and tablet coating with aqueous film-forming polymers is avoided unless the coating dispersion can be applied with rapid drying air below 40 °C because residual moisture at the tablet surface accelerates hydrolysis. The main incompatibility is alkaline or hygroscopic excipients; sorbitol, polyethylene glycol, and unbuffered wet granulation with water alone should be avoided.

Capsule filling for estradiol benzoate is confined to small-batch clinical supply or compounded veterinary preparations where dose adjustment below 0.5 mg is required. The low-dose constraint forces the formulator to avoid direct encapsulation of milled API because the fill weight of a size 3 hard gelatin capsule is normally 80–120 mg, and the drug content would be too low to meter accurately with standard dosator equipment. Instead, a preblend is prepared by geometric dilution with spray-dried lactose monohydrate and pregelatinized starch, lubricated with magnesium stearate at 0.5% w/w for no longer than 3 min in a low-shear V-blender at 20 rpm. The resulting blend is filled into size 3 or size 4 two-piece hard gelatin capsules using an intermittent-motion capsule filler with a dosator nozzle diameter of 4.0 mm and a powder bed height maintained at 50–70 mm. Fill weight variation is checked under Ph. Eur. 2.9.5; for the 80–250 mg fill-weight range, individual deviations must not exceed ±7.5%. Content uniformity is controlled by USP <905>, and the acceptance value should be ≤15.0. Because hard gelatin capsule shells contain 13–15% water, the moisture exchange between the shell and the hygroscopic lactose-starch matrix must be controlled. Storage below 25 °C and 40% RH is required, and if the package is exposed to 40 °C/75% RH stress conditions, hydrolytic degradation of the 3-benzoate ester to 17β-estradiol can exceed the typical total impurity threshold of 1.0% within 3–6 months. The capsule form is therefore not a robust platform for ambient tropical distribution; aluminum-foil blisters with desiccant are the minimum package. In companion animal medicine, estradiol benzoate capsules are used off-label in spayed female dogs with estrogen-responsive urethral sphincter incompetence, but this use depends on national compounding rules and veterinary discretion, because the approved veterinary estriol product differs in potency, half-life, and receptor binding profile.

When Estradiol Benzoate Enters Powder and Premix Operations as a Potent Steroid

Powder and granulated premix operations introduce a different risk: airborne dust and cross-contamination rather than dissolution or compressibility defects. Estradiol benzoate is a hormonal active substance with occupational health requirements that go beyond ordinary pharmaceutical cleaning. Although a globally harmonized occupational exposure limit is not established for the veterinary grade ester, in-house banding should be derived from the no-observed-adverse-effect level of the parent estrogen and the route-specific uncertainty factors. Engineering controls for powder handling therefore include a downflow booth or rigid isolator with HEPA filtration, room differential pressure of −15 Pa to adjacent areas, and split butterfly transfer valves for material charging. The API is not milled in open systems; a jet mill equipped with a cyclone separator and cartridge filter is used if micronization is required, and the milled powder is discharged only after a dust-settling period. For a powder premix intended for subsequent reconstitution into an oral liquid or semi-solid vehicle, geometric dilution with spray-dried lactose monohydrate, dextrose anhydrous, or a maltodextrin carrier is performed in low-shear drum blenders, but electrostatic charge can segregate the API if relative humidity is below 30%. The finished premix is sieved through a 0.500 mm mesh and packaged in laminated aluminum-foil sachets with heat-sealed seams; loss on drying is controlled at ≤2.0% by Ph. Eur. 2.2.32. Granules can be produced by top-spray fluid-bed granulation using hydroxypropyl methylcellulose 3 cP as a binder at 5% w/w solids, inlet air temperature 60–65 °C, product temperature 30–35 °C, and air dew point <8 °C. This process preserves the integrity of the ester bond by limiting water exposure during wetting and providing rapid evaporation. A major incompatibility is alkaline or reactive carriers: calcium carbonate, magnesium oxide, and unbuffered basic fillers should be avoided because surface moisture plus alkalinity accelerates ester hydrolysis. In addition, feed-premix use in food-producing animals is prohibited under Directive 2003/74/EC and Regulation (EU) 2019/6 in the European Union, and export-oriented premix production must be segregated from EU food-animal supply chains to avoid cross-contamination with non-medicated feed.

An oral liquid vehicle based on propylene glycol and ethanol improves the apparent solubility of estradiol benzoate, but it introduces a different set of degradation and packaging constraints. The ester is poorly soluble in water, so an oral drench or solution is typically formulated with 35–45% v/v propylene glycol, 25–35% v/v ethanol 96%, and purified water to dissolve the API at concentrations of 1–5 mg/mL. The solution is prepared under nitrogen sparging because dissolved oxygen combines with the aromatic A-ring of the steroid and generates peroxide-mediated oxidation products that appear as unknown related substances in HPLC analysis. Ethanol and propylene glycol should be checked for peroxide value; a limit below 10 ppm hydrogen peroxide equivalents is appropriate for the finished vehicle before API addition. Storage requires amber type III glass bottles with child-resistant closures and low-density polyethylene or PTFE-faced liner components because the drug substance partitions into unfluorinated rubber and can sorb onto PVC. Chemical stability is more sensitive to water content than to pH in the neutral range: the hydrolysis rate of the 3-benzoate ester increases measurably when the water content exceeds 20% v/v, so water-miscible co-solvent systems with reduced water activity are preferred for a shelf life beyond 18 months at 25 °C. In veterinary use, oral estradiol benzoate solutions may be administered to horses or small companion animals where a veterinarian determines that the injection route is not feasible, but oral bioavailability is limited by first-pass hepatic metabolism, and no harmonized veterinary bioequivalence monograph exists for all species. The dosing precision for oral solutions depends on the supplied measuring device: a syringe adapter and graduated oral syringe calibrated in 0.1 mL increments are used to reduce dosing error, and the label must state the concentration in mg/mL rather than a per-drop instruction because drop size varies with nozzle geometry and liquid surface tension.

What Limits Use in Food-Producing Species Under Modern Veterinary Drug Regulations?

Regulatory constraints are not an afterthought for estradiol benzoate veterinary grade; they materially change which downstream dosage forms are economically and lawfully viable. The European Union framework, established by Directive 2003/74/EC and carried into Regulation (EU) 2019/6, prohibits the use of estradiol 17β and its esters in food-producing animals, with narrowly framed therapeutic exceptions that do not apply to routine synchronization or growth promotion. A tablet, premix, or injectable containing estradiol benzoate intended for cattle, swine, sheep, or goats therefore cannot be placed on the EU market under current law, regardless of whether the finished product meets pharmacopoeial quality standards. This regulatory wall shifts manufacturing and distribution to export-only territories where national residue control programs, maximum residue limits, and withdrawal periods are established. For those markets, batch release must also comply with the analytical requirements of VICH GL18 for residual solvents, Ph. Eur. 2.6.1 for sterility of parenteral products, USP <85> for bacterial endotoxins where injectable products are concerned, and relevant GMP documentation under FDA 21 CFR Part 211 for packaging, equipment cleaning, and process validation. In the companion animal field, the legal basis is different: many jurisdictions allow veterinary compounding or off-label use under specific clinical conditions, but the manufacturing scales are smaller and the documentation burden around batch size, stability protocol, and beyond-use date is much higher. A critical operational boundary is therefore market-specific: a single production line cannot operate under a single regulatory assumption; export injectable batches for beef cattle require residue-control oriented documentation, while small-batch capsules for spayed dogs require compounding-specific documentation rather than full marketing authorization dossiers.